Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROPOFOL vs ETOMIDATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Propofol enhances the activity of gamma-aminobutyric acid (GABA) at GABA-A receptors, leading to increased chloride conductance, neuronal hyperpolarization, and anesthetic effects. It also inhibits N-methyl-D-aspartate (NMDA) receptors and modulates calcium influx via L-type calcium channels.
Etomidate is a nonbarbiturate hypnotic agent that acts as a positive allosteric modulator of the gamma-aminobutyric acid (GABA) type A receptor, enhancing GABA-mediated inhibition in the central nervous system. It produces rapid anesthesia with minimal cardiovascular and respiratory depression.
Induction and maintenance of general anesthesia,Sedation for intubated, mechanically ventilated patients in the ICU,Procedural sedation (e.g., during diagnostic or therapeutic procedures),Treatment of refractory status epilepticus (off-label),Management of severe agitation or delirium (off-label)
Induction of general anesthesia,Procedural sedation (off-label),Rapid sequence intubation (off-label)
Induction: 2-2.5 mg/kg IV bolus. Maintenance: 25-75 mcg/kg/min IV infusion. For sedation: 25-100 mcg/kg/min IV.
Induction: 0.2–0.6 mg/kg IV over 30–60 seconds. Maintenance: 10–20 mcg/kg/min IV continuous infusion.
Terminal elimination half-life: 4-7 hours (after prolonged infusion, context-sensitive half-life increases up to 60 minutes after 8-hour infusion).
Terminal elimination half-life: 2.9–5.3 hours (context: redistribution shortens clinical effect; hepatic impairment prolongs).
Primarily hepatic via conjugation to glucuronide and sulfate; also metabolized by CYP2B6 and CYP2C9. Metabolites are renally excreted.
Etomidate is extensively metabolized in the liver via hydrolysis of the ester side chain by hepatic esterases to its principal metabolite, etomidate carboxylic acid. A minor metabolite is formed via N-demethylation. Metabolites are inactive.
Renal: <1% unchanged; hepatic metabolism to inactive glucuronide and sulfate conjugates, excreted renally (≈88%) and fecally (≈1-2%).
Renal: 75% as metabolite (carboxylic acid), 2% unchanged; fecal/biliary: minimal.
95-99% bound primarily to albumin (≈48%) and alpha-1-acid glycoprotein (≈50%), with minor binding to lipoproteins.
76% bound to albumin.
Initial Vd: 0.2-0.4 L/kg (central compartment); steady-state Vd: 2-10 L/kg (extensive tissue distribution).
Vd: 2.5–4.5 L/kg (large, indicating extensive tissue uptake).
IV: 100%; enteral: negligible due to first-pass metabolism; oral bioavailability <1%.
IV: 100% (only route used clinically).
No dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, use with caution due to propylene glycol accumulation, monitor for metabolic acidosis.
No dose adjustment required for renal impairment. Hemodialysis does not alter dosing. Use caution in severe renal failure due to propylene glycol vehicle if prolonged infusion.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Avoid use or reduce by 75% due to prolonged clearance and risk of hypotension.
No specific adjustment for Child-Pugh class. However, prolonged effect may occur in severe hepatic impairment; reduce induction dose by 50% and titrate to effect.
Induction: 2.5-3.5 mg/kg IV over 30 sec. Maintenance: 125-300 mcg/kg/min for age <3 years; 100-200 mcg/kg/min for age 3-12 years. For sedation: 25-100 mcg/kg/min.
Induction: 0.2–0.6 mg/kg IV (max 40 mg). Age >10 years: use adult dosing. Neonates and infants: reduce dose to 0.3 mg/kg due to higher volume of distribution.
Reduce induction dose to 1-1.5 mg/kg IV; decrease infusion rate by 20-50% due to reduced clearance and increased sensitivity.
Induction: 0.15–0.3 mg/kg IV (50% reduction of adult dose) due to decreased clearance and increased sensitivity. Use lower end of dosing range.
No FDA black box warnings.
Etomidate has been associated with mortality in children. It should not be used in children younger than 6 months of age. (This warning is included in the prescribing information based on FDA labeling; specific text may vary.)
Hypotension and bradycardia: may require fluid resuscitation or vasopressors,Respiratory depression and apnea: must have airway management equipment available,Propofol infusion syndrome (PRIS): rare but fatal with high doses >4 mg/kg/hr for >48 hours; characterized by metabolic acidosis, rhabdomyolysis, hyperkalemia, and cardiac failure,Risk of pancreatitis: monitor lipase if symptoms develop,Abrupt discontinuation may cause withdrawal symptoms after prolonged use,Not recommended for use in patients with propofol allergy or egg/soybean oil hypersensitivity (formulation contains egg lecithin and soybean oil)
Inhibition of adrenal steroidogenesis (adrenal suppression) due to blockade of 11-beta-hydroxylase, leading to decreased cortisol and aldosterone production; may persist for 12-24 hours after single dose,Myoclonic movements during induction (involuntary muscle contractions),Hypotension and bradycardia (less common than with other induction agents),Venous irritation and pain on injection (may be reduced by using larger veins)
Hypersensitivity to propofol or any component of the formulation (including egg lecithin, soybean oil, or disodium edetate),Patients with severe lipid metabolism disorders (e.g., pancreatitis with hypertriglyceridemia),Not for use in general anesthesia in obstetrics (crosses placenta; may cause neonatal depression),Relative: hypovolemia, hemodynamic instability, increased intracranial pressure (use with caution)
Hypersensitivity to etomidate,Patients with acute porphyria (may be porphyrinogenic)
No specific food restrictions. However, propofol is formulated in a lipid emulsion containing soybean oil and egg lecithin, which may interact with high-fat meals theoretically but not clinically significant. Avoid alcohol for 24 hours post-procedure due to additive sedative effects.
No specific food interactions are known. Etomidate is administered intravenously and does not have oral bioavailability. However, concurrent use of drugs that affect CYP3A4 (e.g., grapefruit juice) is not clinically significant due to IV route.
First trimester: Propofol is not associated with major congenital malformations based on limited human data, but animal studies show developmental toxicity at high doses. Second trimester: No clear evidence of fetal harm. Third trimester: Use may cause neonatal respiratory depression, hypotonia, and neurobehavioral effects; risk of fetal bradycardia and hypoxia. Propofol crosses the placenta rapidly.
Etomidate is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxicity and teratogenicity at doses higher than human doses. There are no adequate and well-controlled studies in pregnant women. First trimester exposure may be associated with a slightly increased risk of congenital malformations, but data are limited. Risks to the fetus should be weighed against the benefits of maternal anesthesia. The drug is not recommended during pregnancy unless clearly needed, especially during organogenesis. In the second and third trimesters, etomidate may cause fetal central nervous system depression and respiratory depression if used near term.
Propofol is excreted into breast milk in very low concentrations, with an estimated M/P ratio of 1.2-1.5. The relative infant dose is <0.1% of weight-adjusted maternal dose. Consider discarding milk for 24 hours after administration due to potential sedative effects on the infant.
It is unknown whether etomidate is excreted in human breast milk. The molecular weight (244.3) suggests potential excretion into milk. The milk-to-plasma ratio (M/P) has not been determined. Due to the short half-life (2–5 hours) and use as a single induction dose, transfer to the infant is likely minimal. However, caution is advised. The American Academy of Pediatrics classifies etomidate as 'compatible' with breastfeeding after a single dose, but data are insufficient for repeated or prolonged use. Infants should be monitored for sedation and respiratory depression.
Pregnancy increases volume of distribution and clearance of propofol by 20-50%, primarily due to increased cardiac output and hepatic blood flow. Induction doses may need to be increased by 15-30% to achieve desired effect. Maintenance infusion rates may also require upward titration.
No specific dose adjustments are recommended for etomidate during pregnancy, but the dose should be individualized to achieve the desired level of anesthesia with the lowest effective dose. Physiologic changes in pregnancy (e.g., increased plasma volume, altered protein binding) may affect pharmacokinetics, but etomidate is rapidly redistributed and has a short duration of action. The standard induction dose of 0.2–0.6 mg/kg IV is used. Close monitoring of maternal and fetal status is advised. In cesarean section, lower doses may be considered to reduce fetal depression.
Propofol causes dose-dependent respiratory depression and apnea; always have airway equipment ready. It reduces cerebral metabolic rate and intracranial pressure, making it useful for neuroanesthesia. Pain on injection is common, particularly in small veins; consider lidocaine pretreatment. Propofol infusion syndrome (PRIS) is a rare but fatal complication with prolonged high-dose infusions (>48h, >4 mg/kg/h), characterized by lactic acidosis, rhabdomyolysis, and cardiac failure. Avoid in patients with egg or soy allergy due to lipid emulsion. Use the lower dose for elderly or hemodynamically unstable patients. Monitor triglyceride levels with prolonged use.
Etomidate is an induction agent of choice in hemodynamically unstable patients due to minimal cardiovascular depression. Adrenal suppression occurs even after a single dose, manifesting as decreased cortisol and aldosterone synthesis via 11β-hydroxylase inhibition. Administer slowly over 30-60 seconds to reduce myoclonus and pain on injection. Use a lower dose (0.2-0.3 mg/kg IV) in elderly or debilitated patients. Etomidate is not recommended for rapid sequence intubation in septic shock due to risk of adrenal insufficiency; consider ketamine as alternative. Prolonged infusion is not advised due to propylene glycol vehicle and adrenal suppression.
This medication will cause you to feel very sleepy and lose consciousness quickly.,You may experience a burning or stinging sensation at the injection site; this is common.,Do not drive, operate machinery, or make important decisions for at least 24 hours after receiving this medication.,You might feel groggy, dizzy, or have a headache after waking up.,Inform your doctor if you have any allergies, especially to eggs, soy, or peanuts.,If you will be receiving this medication for a prolonged period, your doctor will monitor your heart, kidneys, and blood tests.
You may experience brief involuntary muscle movements during injection, which are usually harmless.,Tell your doctor if you have adrenal gland problems or are taking corticosteroids.,This drug may cause a temporary decrease in your body's ability to produce stress hormones.,Avoid driving or operating machinery until the effects of the medication have completely worn off.,Report any severe pain at the injection site or unusual weakness after the procedure.
"Propofol, a general anesthetic, may inhibit CYP2C8, the primary enzyme responsible for rosiglitazone metabolism, leading to decreased clearance and elevated plasma concentrations of rosiglitazone. This interaction can potentiate the hypoglycemic effects of rosiglitazone, increasing the risk of hypoglycemia. Clinical vigilance is warranted when these agents are coadministered, especially in patients with diabetes."
"The combination of propofol and methyldopa can lead to an increased risk of severe hypotension and bradycardia due to additive cardiovascular depressant effects. Propofol causes peripheral vasodilation and direct myocardial depression, while methyldopa reduces sympathetic outflow and depletes catecholamines, enhancing propofol's hemodynamic effects. This interaction may result in profound hypotension, reduced cardiac output, and risk of organ hypoperfusion during anesthesia induction and maintenance."
"Propofol, a GABA-A receptor agonist and general anesthetic, depresses myocardial contractility and reduces systemic vascular resistance, leading to hypotension and bradycardia. Pindolol, a non-selective beta-blocker with intrinsic sympathomimetic activity, can blunt the compensatory tachycardia in response to propofol-induced vasodilation and myocardial depression. Concurrent use may result in additive negative chronotropic and inotropic effects, potentially causing severe bradycardia, hypotension, or reduced cardiac output, especially in patients with compromised cardiac function or hypovolemia."
"Concurrent administration of etomidate and fluoxetine may potentiate the anesthetic and sedative effects, as fluoxetine inhibits CYP3A4 which is involved in the metabolism of etomidate, leading to increased etomidate plasma concentrations and prolonged recovery time. Additionally, both drugs can cause QTc interval prolongation, increasing the risk of torsades de pointes and other ventricular arrhythmias. Patients may experience enhanced central nervous system depression, respiratory depression, and hypotension."
"The combination of Promazine, a phenothiazine antipsychotic with strong alpha-adrenergic blocking activity, and Etomidate, a non-barbiturate hypnotic used for induction of anesthesia, can lead to an increased risk of hypotension due to additive vasodilatory effects. Promazine's alpha-1 receptor antagonism impairs compensatory vasoconstriction, while Etomidate suppresses adrenal cortisol synthesis, potentially blunting the stress response and further reducing hemodynamic stability. Clinically, this interaction may result in profound hypotension, especially in hypovolemic or elderly patients, requiring careful dose titration and monitoring."
"The coadministration of oxazepam, a benzodiazepine that enhances GABA-A receptor activity, with etomidate, a non-barbiturate anesthetic that also potentiates GABA-A receptor function, results in additive central nervous system (CNS) depression. This synergistic interaction can lead to excessive sedation, respiratory depression, hypotension, and prolonged recovery from anesthesia. Patients are at increased risk of apnea, hypoxia, and hemodynamic instability, particularly during induction and maintenance of anesthesia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROPOFOL vs ETOMIDATE, answered by our medical review team.
PROPOFOL is a General Anesthetic that works by Propofol enhances the activity of gamma-aminobutyric acid (GABA) at GABA-A receptors, leading to increased chloride conductance, neuronal hyperpolarization, and anesthetic effects. It also inhibits N-methyl-D-aspartate (NMDA) receptors and modulates calcium influx via L-type calcium channels.. ETOMIDATE is a General Anesthetic that works by Etomidate is a nonbarbiturate hypnotic agent that acts as a positive allosteric modulator of the gamma-aminobutyric acid (GABA) type A receptor, enhancing GABA-mediated inhibition in the central nervous system. It produces rapid anesthesia with minimal cardiovascular and respiratory depression.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROPOFOL and ETOMIDATE depend on the specific clinical indication. These are both General Anesthetic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROPOFOL is: Induction: 2-2.5 mg/kg IV bolus. Maintenance: 25-75 mcg/kg/min IV infusion. For sedation: 25-100 mcg/kg/min IV.. The standard adult dose of ETOMIDATE is: Induction: 0.2–0.6 mg/kg IV over 30–60 seconds. Maintenance: 10–20 mcg/kg/min IV continuous infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining PROPOFOL and ETOMIDATE. The risk or severity of adverse effects can be increased when Propofol is combined with Etomidate. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. PROPOFOL is classified as Category A/B. First trimester: Propofol is not associated with major congenital malformations based on limited human data, but animal studies show developmental toxicity at high doses. Second tr. ETOMIDATE is classified as Category C. Etomidate is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxicity and teratogenicity at doses higher than human doses. There are no adequate and well-co. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.